Presented by Cello Health BioConsulting, now part of Lumanity


  • Danielle Marra, MS, MBA, Principal, BioConsulting, Autoimmune & Inflammatory Diseases Co-Lead, Lumanity
  • David Lomb, PhD, Principal, BioConsulting, Autoimmune & Inflammatory Diseases Co-Lead, Lumanity


  • Gary D. Glick, PhD, President, CEO, IFM Therapeutics
  • James Mathew, PhD, Professor of Surgery & Microbiology-Immunology, Northwestern University

Autoimmune diseases represent the largest pharmaceutical market by revenue globally. Advances in technology and our understanding of the immune system are now ushering in several new immunomodulatory approaches to autoimmune disease, including cell-based therapies, antigen-specific therapies, novel antibody/protein approaches, and even new cytokine/small molecule therapeutics. With the major autoimmune markets – most notably rheumatoid arthritis and psoriasis – near peak maturity and biosimilars on the horizon, it remains to be determined how exactly this new wave of pioneering, yet potentially expensive technology will be used. Are we on the verge of truly paradigm-shifting treatments across autoimmune diseases or will therapies derived from these novel technologies be relegated to only a handful of niche markets? Join our webinar as we look to address these issues and discuss the exciting potential of these innovative approaches to autoimmune diseases.